Activation of Cyclic Adenosine Monophosphate Pathway Increases the Sensitivity of Cancer Cells to the Oncolytic Virus M1
Kai Li(China University of Geosciences (Beijing)), Guangmei Yan(Sun Yat-sen University), Yaqian Tan(Sun Yat-sen University), Jialuo Mai(Sun Yat-sen University), Jianguang Qiu(Sun Yat-sen University), Jun Hu(Yichang Central People's Hospital), Liwu Fu(Sun Yat-sen University), Lipeng Tang(Guangzhou University of Chinese Medicine), Min Yan(Dalian Institute of Chemical Physics), Jing Cai(Sun Yat-sen University), Fan Xing(Sun Yat-sen University), Bingzheng Lu(Sun Yat-sen University), Phillip W.L. Tai(University of Massachusetts Chan Medical School), Fang Wang(Sun Yat-sen University), Yuan Lin(Sun Yat-sen University), Wenli Chen(Sun Yat-sen University), Haipeng Zhang(Jinan University), Wei Yin, Yuan Li(Sun Yat-sen University), Wenbo Zhu(Sun Yat-sen University), Xiao Xiao(Sun Yat-sen University), Xingwen Su(Sun Yat-sen University), Jiankai Liang(Sun Yat-sen University), Pengxin Qiu, Guangping Gao(University of Massachusetts Chan Medical School)
Cited by 44
Related Papers
Viral vector platforms within the gene therapy landscape
|Signal Transduction and Targeted Therapy|2021|1.3k
KRAS mutation: from undruggable to druggable in cancer
|Signal Transduction and Targeted Therapy|2021|1k
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
Adeno-associated virus as a delivery vector for gene therapy of human diseases
|Signal Transduction and Targeted Therapy|2024|664